On November 11, 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, reported that data from its AIPAC, TACTI-002 and TACTI-003 studies have been published in abstracts available via the links below on the SITC (Free SITC Whitepaper) 2021 Annual Meeting’s official website or the Company’s website (Press release, Immutep, NOV 11, 2021, View Source [SID1234595396]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Three poster presentations with additional data and commentary that are not included in the abstracts will be available on View Source from 12 November 2021, at 7 am EST and made available on Immutep’s website at www.immutep.com.

TACTI-002
Title: Results from a Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC).
Abstract: View Source
TACTI-003
Title: A Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients unselected for PD-L1 expression in first line metastatic head and neck squamous cell carcinoma (HNSCC).
Abstract: View Source
AIPAC
Note: A separate announcement detailing the AIPAC results has also been released today.
Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000

ABN: 90 009 237 889

Title: Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC.
Abstract: View Source
Webcast Details
Immutep will present the AIPAC data in a global webcast for investors. Details are as follows:
Date & Time 8.00 am AEDT (Sydney) Wednesday 17 November 2021
4.00 pm EST (New York) Tuesday 16 November 2021
10.00 pm CET (Berlin) Tuesday 16 November 2021
Register: View Source
Questions: Investors are invited to submit questions in advance via [email protected].

On November 11, 2021 Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, reported that the Company will participate in the Stifel 2021 Virtual Healthcare Conference from November 15-17, 2021 (Press release, Silverback Therapeutics, NOV 11, 2021, View Source [SID1234595345]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Laura Shawver, Ph.D., Silverback’s Chief Executive Officer, and Valerie Odegard, Ph.D., Silverback’s President and Chief Scientific Officer, will participate in a fireside chat on Wednesday, November 17, 2021 at 2:40 PM ET (11:40 AM PT). The live webcast of the event will be available on Silverback’s investor relations website and a replay will be available for 30 days following the event. Members of the Silverback management team will also host investor meetings during the conference.

On November 11, 2021 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported that management will participate in the following investor conferences (Press release, ORIC Pharmaceuticals, NOV 11, 2021, View Source [SID1234595343]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies London Health Conference – Participating in a virtual fireside chat on Thursday, November 18, 2021, at 8:00 a.m. GMT.

Evercore ISI 4th Annual HealthconX Conference – Participating in a virtual fireside chat on Thursday, December 2, 2021, at 3:55 p.m. ET.
Webcasts of the fireside chats will be available through the investor section of the company’s website at www.oricpharma.com. Replays of the webcasts will be available for 90 days following the events.

On November 11, 2021 Emergent BioSolutions Inc. (NYSE: EBS) reported that its Board of Directors has authorized management to repurchase up to $250 million of the company’s common stock from time to time on the open market or in privately negotiated transactions (Press release, Emergent BioSolutions, NOV 11, 2021, View Source [SID1234595335]). This repurchase authorization expires on November 11, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As part of a balanced capital management plan, we believe the company’s stock can represent an attractive investment opportunity," said Robert G. Kramer, president and chief executive officer at Emergent BioSolutions. "This announcement demonstrates our confidence in Emergent’s business and the strength of our balance sheet and cash position, providing the flexibility to implement this program while simultaneously pursuing opportunities to invest and grow the business both organically and through potential acquisitions."

The timing and amount of any shares repurchased will be determined by the company’s management based on its evaluation of market conditions and other factors, consistent with its insider trading policy. Repurchases may also be made under a pre-established trading plan under Rule 10b5-1 that might result in shares being repurchased when the company might otherwise be precluded from doing so. The repurchase program may be suspended or discontinued at any time. Any repurchased shares will be held in treasury shares and will be available for use in connection with the company’s stock plans and for other corporate purposes.

The repurchase program will be funded using the company’s cash on hand and cash from operations. As of September 30, 2021, the company had cash and cash equivalents of $403.8 million.

The company had approximately 53.7 million shares of common stock outstanding as of September 30, 2021.

On November 11, 2021 Gamida Cell Presented The Corporate Presentation (Presentation, Gamida Cell, NOV 11, 2021, View Source [SID1234595333]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!